



Exelixis Announces November 7th Webcast of Third Quarter 2012 Financial Results Conference Call

October 25, 2012

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 25, 2012-- Exelixis, Inc. (NASDAQ: EXEL) will release its third quarter 2012 financial results on Wednesday, November 7, 2012, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the Company's financial results, financial outlook, and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

An archived replay of the webcast will be available on the Event Calendar page under Investors at <http://www.exelixis.com> and via phone until 11:59 p.m. PST on December 7, 2012. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 43220636.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (formerly known as XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.



Source: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com